In the presented patient, hypokalaemia was observed at the time of first admission, followed by hypokalaemia, elevated levels of renin and aldosterone, as well as hypomagnesemia or hyperphosphatemia one year after initiation of SGLT2 inhibitor therapy (which is not observed in Bartter syndrome type II). The gene discussed is SLC5A2; the disease is Hypomagnesemia.